Tyrosine kinase inhibitor therapy for acute myeloid leukemia with late-appearing Philadelphia chromosome. 2012

Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D016296 Mutagenesis Process of generating a genetic MUTATION. It may occur spontaneously or be induced by MUTAGENS. Mutageneses
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
May 2008, Pediatric blood & cancer,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
August 1990, Cancer genetics and cytogenetics,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
April 2008, Leukemia,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
July 2019, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
June 2012, World journal of stem cells,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
July 2019, Cureus,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
October 2019, Cancer science,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
April 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
November 2013, The Annals of pharmacotherapy,
Jun Aoki, and Kazuhiko Kakihana, and Takeshi Kobayashi, and Yuka Hirashima, and Hideki Akiyama, and Kazuteru Ohashi, and Hisashi Sakamaki
January 2017, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Copied contents to your clipboard!